Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Lacosamide is indicated to treat partial-onset seizures
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
10+ emerging markets, Japan & ANZ transition in final phase
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Subscribe To Our Newsletter & Stay Updated